- Home
- XYF vs ENGN Comparison
XYF vs ENGN Comparison
Compare XYF & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XYF
- ENGN
- Stock Information
- Founded
- XYF 2014
- ENGN 1999
- Country
- XYF China
- ENGN Canada
- Employees
- XYF N/A
- ENGN N/A
- Industry
- XYF Finance: Consumer Services
- ENGN
- Sector
- XYF Finance
- ENGN
- Exchange
- XYF Nasdaq
- ENGN Nasdaq
- Market Cap
- XYF 385.0M
- ENGN 293.1M
- IPO Year
- XYF 2018
- ENGN N/A
- Fundamental
- Price
- XYF $8.04
- ENGN $6.08
- Analyst Decision
- XYF
- ENGN Strong Buy
- Analyst Count
- XYF 0
- ENGN 8
- Target Price
- XYF N/A
- ENGN $30.38
- AVG Volume (30 Days)
- XYF 40.8K
- ENGN 188.1K
- Earning Date
- XYF 11-26-2024
- ENGN 01-27-2025
- Dividend Yield
- XYF 4.23%
- ENGN N/A
- EPS Growth
- XYF 2.79
- ENGN N/A
- EPS
- XYF 3.88
- ENGN N/A
- Revenue
- XYF $763,521,851.00
- ENGN N/A
- Revenue This Year
- XYF N/A
- ENGN N/A
- Revenue Next Year
- XYF N/A
- ENGN N/A
- P/E Ratio
- XYF $2.13
- ENGN N/A
- Revenue Growth
- XYF 16.99
- ENGN N/A
- 52 Week Low
- XYF $3.48
- ENGN $4.42
- 52 Week High
- XYF $8.59
- ENGN $18.40
- Technical
- Relative Strength Index (RSI)
- XYF 66.09
- ENGN 26.04
- Support Level
- XYF $7.82
- ENGN $8.00
- Resistance Level
- XYF $8.35
- ENGN $7.97
- Average True Range (ATR)
- XYF 0.46
- ENGN 0.72
- MACD
- XYF 0.12
- ENGN -0.24
- Stochastic Oscillator
- XYF 84.80
- ENGN 2.22
About XYF X Financial each representing six
X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, and guarantee services provided.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.